NCT07739277

Brief Summary

The aim of this prospective, randomized controlled trial is to compare the analgesic efficacy of transverse versus longitudinal ultrasound probe orientations during Serratus Anterior Plane (SAP) block in patients undergoing breast surgery. The study hypothesizes that the longitudinal approach (probe parallel to the ribs) may provide better craniocaudal spread of the local anesthetic, thereby resulting in lower postoperative Visual Analog Scale (VAS) scores and reduced opioid consumption compared to the standard transverse approach.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
6mo left

Started Aug 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 28, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 31, 2026

Completed
17 days until next milestone

Study Start

First participant enrolled

August 17, 2026

Expected
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 8, 2027

11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 19, 2027

Last Updated

July 31, 2026

Status Verified

July 1, 2026

Enrollment Period

6 months

First QC Date

July 28, 2026

Last Update Submit

July 28, 2026

Conditions

Fascial Plane BlockPain, PostoperativeBreast SurgeryAcute PainMastectomy

Keywords

Serratus Anterior Plane BlockRegional AnesthesiaPostoperative AnalgesiaBreast Surgery

Outcome Measures

Primary Outcomes (1)

  • Postoperative Pain Intensity

    Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) at rest. Pain assessment will be made at 4 hour after surgery.

    4 hour after surgery

Secondary Outcomes (5)

  • Postoperative Pain Intensity

    Up to 24 hours

  • Postoperative Pain Intensity

    Up to 24 hours

  • Total Postoperative Opioid Consumption

    Up to 24 hours

  • Area Under Curve for Pain

    Up to 24 hours

  • Assessment of Sensory Blockade Extent

    Evaluated at 20 minutes following block administration.

Study Arms (2)

Transverse SAP Block

ACTIVE COMPARATOR

Patients will receive an ultrasound-guided Serratus Anterior Plane (SAP) block at the 4th rib level. The ultrasound probe will be placed in a transverse orientation (perpendicular to the ribs). A total of 20 mL of 0.375% bupivacaine will be injected into the fascial plane.

Procedure: Transverse SAP Block

Longitudinal SAP Block

ACTIVE COMPARATOR

Patients will receive an ultrasound-guided Serratus Anterior Plane (SAP) block at the 4th rib level. The ultrasound probe will be placed in a longitudinal orientation (parallel to the ribs in the craniocaudal axis). A total of 20 mL of 0.375% bupivacaine will be injected into the fascial plane.

Procedure: Longitudinal SAP Block

Interventions

Transverse SAP BlockPROCEDURE

Transverse serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.

Transverse SAP Block
Longitudinal SAP BlockPROCEDURE

Longitudinal serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.

Longitudinal SAP Block

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged between 18 and 75 years
  • American Society of Anesthesiologists (ASA) physical status I, II, or III
  • BMI between 18 - 30 kg/m2
  • Patients scheduled for elective breast surgery
  • Ability to provide written informed consent

You may not qualify if:

  • Known allergy to local anesthetics
  • Infection at the injection site
  • Severe coagulopathy or use of anticoagulants
  • Chronic opioid use or history of neuropathic pain

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Etlik City Hospital

Ankara, Yenimahalle\Ankara, 06170, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, PostoperativeAcute Pain

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Central Study Contacts

İbrahim MD Topcu

CONTACT

05437860316ibrahimtpc78@gmail.com

Musa Ass. Prof Zengin

CONTACT

05071302750musazengin@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 28, 2026

First Posted

July 31, 2026

Study Start (Estimated)

August 17, 2026

Primary Completion (Estimated)

February 8, 2027

Study Completion (Estimated)

February 19, 2027

Last Updated

July 31, 2026

Record last verified: 2026-07

Locations

TU(1)